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Abstract
Primary cells are often used to study viral replication and host-virus interactions as their antiviral pathways have not been
altered or inactivated; however, their use is restricted by their short lifespan. Conventional methods to extend the life of
primary cultures typically utilize viral oncogenes. Many of these oncogenes, however, perturb or inactivate cellular antiviral
pathways, including the interferon (IFN) response. It has been previously shown that expression of the telomerase reverse
transcriptase (TERT) gene extends the life of certain cell types. The effect that TERT expression has on the innate antiviral
response to RNA- and DNA-containing viruses has not been examined. In the current study, we introduced the human TERT
(hTERT) gene into a primary human embryonic lung (HEL-299) cell strain, which is known to respond to the type I IFN, IFN-b.
We show that the resulting HEL-TERT cell line is capable of replicating beyond 100 population doublings without exhibiting
signs of senescence. Treatment with IFN-b resulted in the upregulation of four model IFN stimulated genes (ISGs) in HEL-299
and HEL-TERT cells. Both cell lines supported the replication of herpes simplex virus type 1 (HSV-1) and vesicular stomatitis
virus (VSV) and impaired the replication of both viruses upon IFN-b pretreatment. Introduction of the viral oncoprotein,
simian virus 40 (SV40) large T-antigen, which is frequently used to immortalize cells, largely negated this effect. Taken
together, our data indicate that expression of hTERT does not alter type 1 IFN signaling and/or the growth of two viruses,
making this cell line a useful reagent for studying viral replication and virus-cell interactions.
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Introduction
In performing studies that examine cellular immune responses
to viral infections, it is often necessary to work with primary cells,
as the efficacy of intrinsic and innate immune pathways are
frequently diminished in immortalized cells [1–4]. One disadvan-
tage of using primary cells is their limited proliferative capacity in
cell culture, which is due in part, to the progressive shortening of
telomeres [5].
Telomeres are repetitive nucleoprotein structures that serve to
cap the ends of chromosomes, facilitating their replication, and
prevent their ends from appearing as DNA breaks [6]. Telomeres
are maintained by a complex known as telomerase, whose essential
core consists of the catalytic subunit telomerase reverse transcrip-
tase (TERT) and the telomerase RNA template component
(TERC) [7,8]. Along with a number of other factors, TERT is
loaded onto the 39 overhang of existing telomeric DNA and
utilizes TERC as a template to add repeats of a guanine-rich
sequence, 59TTAGGG39, in all vertebrates; concordantly, DNA
primase and DNA polymerase are recruited to the new telomeric
repeats, subsequently synthesizing the complementary 59 strand
[6]. In the absence of active telomerase, erosion of the telomeres
occurs with each successive round of replication, resulting in the
loss of telomeric (,100 bps) sequence [9,10]. Once telomeres are
reduced from their normal 15 kb length to ,4 kb, DNA damage
sensors trigger p53- and pRb-dependent mechanisms that result in
cellular senescence, inducing a G1 cell cycle arrest [11].
Replicative senescence is thought to be a mechanism of cellular
lifespan regulation, preventing diseases such as cancer, and is
intrinsic to the health of an organism [12–15]. However, for
technical reasons it can be desirable to extend the proliferative
capacity and prevent the senescence of a primary cell culture or
strain. One way to avoid or reverse replicative senescence is
transformation with viral oncogenes, such as the simian virus 40
(SV40) large T antigen (TAg) or the human papillomavirus (HPV)
E6 and E7 proteins [16–18]. In both cases, these viral proteins
reverse senescence through the inactivation of p53 and/or pRb.
While this allows cells to resume progression through the cell cycle
and replicate, these cells still undergo telomeric erosion and
ultimately undergo a phenomenon termed crisis [16], where
massive cell death occurs due to gross genomic rearrangements
and instability in the absence of telomeres. While the estimated 1
in 107 cells (for human cells) that survive crisis exit immortalized
[19,20], this transformation results in the dysregulation of several
cellular pathways, including the antiviral type I interferon (IFN)
response [1].
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The IFN response is an innate antiviral pathway that, upon
detection of viral molecular patterns, results in the production and
release of the cytokine and type 1 IFN, IFN-b [21–23]. IFN-b
binds to its cognate receptor in both an autocrine and paracrine
manner, activating a signal transduction cascade that ultimately
upregulates numerous interferon-stimulated genes (ISGs), which
function to limit viral replication. The IFN response serves as a
major restriction point for many viruses as evidenced by the
increased pathogenesis of these viruses in animal models in which
either the type I IFN receptor, IFNAR, or a key signaling
molecule, STAT1, are deleted [24–30]. One example is herpes
simplex virus type-1 (HSV-1), a large double-stranded DNA-
containing virus that is estimated to infect 70–90% of adults [31].
Notably, HSV-1 encodes for viral proteins that inactivate or delay
this IFN response [32,33]. Studies examining how HSV-1
counteracts the IFN response are often performed in primary
cultures or cell strains, such as human embryonic lung (HEL) cells,
because these cells possess a robust IFN response and phenotypes
that are apparent in HEL cells are often greatly diminished in
transformed lines [1,34]. A potential drawback with using HEL
cells is their rapid progression into senescence.
As part of their differentiation program, human cells cease
expressing hTERT, while continuing to produce other essential
telomerase subunits such as TERC [35]. It has been shown by a
number of labs that the lifespan of fibroblasts is efficiently
extended by the reintroduction of hTERT into these cells [36,37].
Exogenous expression of hTERT presumably allows terminally
differentiated fibroblasts to resume the extension of their
telomeres, delaying or avoiding the production of signals that
trigger replicative senescence and in turn prevents the chromo-
somal damage encountered by replication through crisis [38].
Unlike transformation with viral oncogenes, fibroblasts that
exogenously express hTERT do not, for the most part, exhibit
an oncogenic phenotype [39]. Notably, the effect that life-
extension by exogenous expression of hTERT on innate antiviral
pathways, and in particular the IFN response, has not been
examined.
Here we report the creation of a life-extended HEL cell line via
transduction of a human diploid primary-like cell strain, HEL-299,
with a retrovirus encoding hTERT. HEL-299s were chosen as a
parental cell line since they are both capable of supporting high
levels of HSV-1 and VSV replication and retain a strong innate
immune restriction of viral replication [40,41]. Our results show
that the derivative cell line, HEL-TERT, unlike the parental cells,
replicated to at least 100 population doublings, exhibited
telomerase activity, and failed to undergo either replicative
senescence or crisis. Morphologically, HEL-TERT cells appeared
indistinguishable from HEL-299 cells. HEL-TERTs responded to
IFN-b by upregulating representative ISGs and supported the
replication of HSV-1 and VSV to similar levels as HEL-299 cells.
Additionally, the introduction of the SV40 large TAg counteracted
the IFN-b-directed restriction of HSV-1 and VSV replication. In
summary, our data indicate that hTERT extends the replicative
potential of human fibroblasts while not perturbing the type 1 IFN




HEL-299 cells from the American Type Culture Collection
(CCL-137), HEL telomerase life-extended (HEL-TERT), and
HEL-TERT SV40 large TAg transformed (HEL-TERT-T) cells
(the latter two of which were created as part of this work, as
detailed below) were maintained in Minimum Essential Medium
Eagle Alpha Modification (aMEM) containing 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 10 U/mL penicillin, and 10 U/
mL streptomycin. In addition, HEL-TERT cells were kept under
drug selection using hygromycin-B (Sigma) at 50 mg/mL while
HEL-TERT-T cells were maintained under selection with
hygromycin-B at 50 mg/mL and phleomycin at 10 mg/mL. HeLa,
GP2-293, Vero, and L7 (Vero cells that contain the ICP0 gene
[42]) cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 5% FBS, 2 mM L-glutamine, 10
U/mL penicillin, and 10 U/mL streptomycin.
HEL-299 (passage 4) cells were transduced with the retroviral
vector, pMX-hTERT-hygro vector. pMX-hTERT-hygro was
created by subcloning the hTERT (catalytic subunit of human
telomerase) and hygromycin resistance genes from the vector,
pBABE-hygro-hTERT [43] (Addgene plasmid 1773), into the
retroviral vector, pMX-GFP [44]. A control vector, pMX-
dTERT-hygro, was created by excising a BamHII fragment,
which removes the N-terminal 849 residues of hTERT (Uniprot:
O14746) [45] (including the TERC-interaction and most of the
reverse-transcriptase domains), from pMX-hTERT-hygro. Retro-
viral stocks were generated using the Pantropic Retroviral
Expression System (Clontech) as recommended by the manufac-
turer. HEL-299 cells were transduced with filtered retroviral stocks
and two days later placed under selection with hygromycin B at
100 mg/mL, which was lowered to 50 mg/mL 7 days later for
subsequent culturing. HEL-TERT SV40 large TAg-expressing
cells were created by transduction with the vector, pLVX-LgT-
zeo. pLVX-LgT-zeo was created by subcloning the CMV
promoter, SV40 TAg ORF, SV40 early promoter, and zeomycin
resistance genes from pBABE-zeo largeTcDNA [46] (Addgene
plasmid 1779) into the lentiviral vector, pLVX-AcGFP-N1
(Clontech), replacing the region containing the CMV promoter,
AcGFP ORF, phosphoglycerate kinase promoter, and puromycin
resistance genes. Lentiviral stocks were prepared essentially as
described above for pMX-hTERT-hygro with the inclusion of the
lentiviral packaging vector, psPAX2 (Addgene plasmid 12260)
during lentiviral stock preparation. HEL-TERT cells were
transduced with filtered lentiviral stocks and two days later placed
under selection with phleomycin (Invivogen) at 20 mg/mL for 42
days, which was lowered to 10 mg/mL for long term culturing.
KOS was the wild type strain of HSV-1 used in our viral
experiments [47]. 7134 is an ICP0-null mutant HSV-1 strain in
which the E. coli lacZ gene has replaced the ICP0 open reading
frame [48]. KOS and 7134 were grown on Vero cells and titered
on Vero or L7 cells, respectively [49,50]. The vesicular stomatitis
virus recombinant, VSV-eGFP, contains the enhanced green
fluorescent protein gene between the G and L genes [51] and was
a gift from Dr. Asit Pattnaik. VSV-eGFP stocks were grown and
titered on Vero cells. Sendai virus (SeV, Cantrell strain) was
purchased from Charles River Labratories.
b-galactosidase Staining
To detect senescence, HEL-299, and moderate and high
passage HEL-TERT cells were plated at 16105 cells per well in
12 well plates and grown to confluence. The cells were fixed in
3.7% formaldehyde, washed twice with 16 phosphate buffered
saline (PBS), and stained for b-galactosidase activity as previously
described [52]. Cells were viewed with a Nikon Eclipse TE2000-U
microscope and photographed with a digital camera (Canon).
Life-Extension Characterization
Low passage HEL-299 and HEL-TERT cells were plated in 60
mm dishes at 1–26105 cells per dish. Prior to reaching confluence,
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the cells were trypsinized, counted with a hemocytometer, and
replated at the above-mentioned amount. This was repeated until
cells reached senescence and died. Using cell counts and days in
culture, the population doublings were determined for each cell
line.
Telomeric Repeat Amplification Protocol (TRAP) Assay
TRAP assays were performed essentially as described [53].
26105 HEL-299, HEL-TERT, and HeLa cells were collected,
pelleted, and frozen at 280uC. The cell pellets were resuspended
in 200 mL of CHAPS lysis buffer (0.5% CHAPS, 10 mM Tris-HCl
pH 7.5, 1 mM MgCl2, 1 mM EGTA, 3.5% 2-mercaptoethanol,
10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 mg/mL
aprotinin, and 1 mg/mL leupeptin) and incubated on ice for 30
minutes before cell pellets were collected by centrifugation.
Telomeric repeats were amplified in a solution of 10 ng of cell
extract, 16Taq buffer (NEB), 0.2 mM dNTPs, 0.04 mg/mL of T4
Gene 32 Protein (NEB), and 2 U of the Taq polymerase (NEB)
containing 0.5 ng/mL of the primers: TS (59-AATCCGTCGAG-
CAGAGTT-39) and ACX (59-GCGCGG(CTTACC)3CTAACC-
39) by polymerase chain reaction (PCR) in an MJ Mini Personal
Thermal Cycler (Bio-Rad). Final PCR products were gel
electrophoresed on 20% polyacrylamide gel, visualized with
ethidium bromide staining, and photographed with a VisiDoc-It
Imaging System (UVP).
Quantitative Reverse Transcriptase Real Time PCR
HEL-299, HEL-TERT, and HEL-TERT-T cells were plated at
16105 cells per well. Twenty-four hours post-plating, cells were
mock treated or treated with human IFN-b at 1000 U/mL (AbD
Serotec). At 9 h post treatment, cells were washed twice with PBS
and harvested in Trizol (Invitrogen) to isolate total RNA. RNA
was converted into cDNA using iScript cDNA synthesis kit (Bio-
Rad) according to manufacturers recommendations. For each
sample, real time PCR was performed using FastStart SYBR green
master (Rox) (Roche) in a StepOnePlus Real-Time PCR System
(Applied Biosystems). Transcripts were amplified using the
following primer sets: hTBP (59-TGCACAGGAGCCAAGAGT-




IFIT2 (59-ACGCATTTGAGGTCATCAGGGTG-39 and 59-
CCAGTCGAGGTTATTTGGATTTGGTT-39) [54], and Mx1
(59-AGAAGGAGCTGGAAGAAG-39 and 59-CTGGAGCAT-
GAAGAACTG-39) [55]. All transcript levels were normalized to
hTBP.
Western Blot
HEL-299, HEL-TERT, and HEL-TERT-T cells were plated at
1.56105 of cells per well in a 12-well plate. 24 h later, cells were
either mock treated or treated with IFN-b at 1000 U/mL for 16
hours before being washed with PBS and then lysed into Red
Loading Buffer (62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10%
glycerol, 0.01% phenol red, 42 mM DTT) plus with protease
inhibitors (1 mg/mL aprotinin, 1 mg/mL leupeptin, 1 mM
phenylmethylsulfonyl fluoride). Samples were resolved on a 4–
12% Bis-Tris gradient polyacrylamide gel, transferred to nitrocel-
lulose, blocked with 5% BSA in Tris-buffered saline with 0.1%
Tween-20 (TBS-T) for 1 h at room temperature. Membranes were
probed with an antibody against IFIT1 (PA3-848, Thermo
Scientific) diluted in 5% BSA/TBS-T overnight at 4uC. Mem-
branes were washed three times with TBS-T, probed with HRP-
conjugated goat-anti-rabbit IgG diluted in 5% BSA/TBS-T for 1
h at room temperature, washed three times with TBS-T,
developed with chemiluminescent substrate (Femto ECL, Pierce
Laboratories), and detected using an Image Station 4000R
(Kodak) and Carestream Molecular Imaging software. The
membranes were then striped and probed with b-actin ((I-19)-R,
Santa Cruz Biotechnology) as previously described [40]. Images
were assembled using Adobe Photoshop and Adobe Illustrator
(Adobe Systems).
Plaque Reduction Assays
Plaque assays for KOS and 7134 on HEL-299, HEL-TERT,
and HEL-TERT-T cells (2/+ IFN-b) were carried out as
previously described [40]. Images of viral plaques were captured
by scanning the immunohistochemically stained plates with a
flatbed scanner (Canon).
HSV-1 Viral Yield Assays
To examine HSV-1 productive infection, HEL-299, HEL-
TERT, and HEL-TERT-T cells were plated at 16105 cells per
well in 12 well plates. One day post-plating, cells were mock-
treated or treated with 1000 U/mL of human IFN-b. Sixteen
hours post-treatment, cells were infected with either KOS or 7134
at 5 plaque forming units (PFU)/cell, washed with PBS (2/+ IFN-
b) after 1 hour to remove unabsorbed virus, and placed back in
growth medium (2/+ IFN-b). At 24 hours post-infection, cells
were harvested and frozen at 280uC. Virally infected samples
were thawed and sonicated, and standard plaque assays were
performed on either Vero cells (for KOS) or L7 cells (for 7134) to
determine viral titers.
VSV Viral Yield Assays
To measure VSV replication, HEL-299, HEL-TERT, and
HEL-TERT-T cells were plated, mock-treated or treated with
IFN, and infected as for the HSV-1 yield assays except that cells
were infected with VSV-eGFP at 0.1 PFU/cell. At 24 hours post-
infection, cells were harvested and frozen at 280uC. Virally
infected samples were thawed and sonicated, and standard plaque
assays were performed on Vero cells to determine viral titers.
Antiviral Cytokine-Production Assay
To assess the ability of various cell lines to produce antiviral
cytokines, HEL-299, HEL-TERT, or HEL-TERT-T cells were
plated at 16105 in 12-well plates. The next day, the cells were
either mock infected with serum-free aMEM or infected with SeV
at 100 hemagglutination units (HAU) per 106 cells in serum-free
medium for 1 hour, after which the virus was removed from the
cells and fresh aMEM containing 10% FCS was added to the cells.
Twenty-four hours post infection, SeV-infected HEL cells were
irradiated with ultraviolet light to inactive the virus. To test for the
production of antiviral cytokines secreted from these cells,
duplicate Vero cell monolayers (26105 cells per well in 12-well
plates) were exposed to HEL supernanes. In addition, one set of
Vero cells were treated with either fresh aMEM or aMEM
containing IFN-b at 1, 10, 100, or 1000 U/mL as positive
controls. Six hours later, untreated and treated Vero cells were
infected with VSV-eGFP at ,200 PFU/well. At 1 hour post
infection, the Vero cells were overlaid with aMEM containing
10% FCS and 1% methylcellulose. Twenty-four hours post-VSV
infection, the methylcellulose was removed, Vero cells were
washed with PBS and fixed with 3.7% formaldehyde, and
fluorescent plaques were counted.
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Results
HEL-TERT Cells Exhibit an Expanded Proliferative Capacity
HEL-299 cells are a primary strain that have been used to study
viral replication and the type 1 IFN response [40,56,57]. This cell
strain, nonetheless, can only be passaged in culture a limited
number of times before undergoing senescence [58]. We wanted to
determine whether ectopic expression of hTERT in HEL-299 cells
would allow for a longer period of culturing. HEL-299s were
transduced with a retrovirus encoding both hTERT and
hygromycin resistance. The resulting antibiotic resistant mass
population, hereafter called HEL-TERT, were then used in
subsequent experiments. To first examine whether hTERT
conferred an extended ability to replicate, HEL-299 and HEL-
TERT cells were maintained in culture for an extended period of
time, comparing the number of population doublings to days in
culture. As expected, HEL-299s proliferated just under 60 days in
culture and underwent a total of 23.5 population doublings (from
two experiments); at which point the cells ceased to divide and
underwent widespread cell death two weeks later (Figure 1). It
should be noted that in a couple of instances, HEL-299 cells were
able to undergo approximately 35 population doublings (data not
shown). In contrast, the HEL-TERT cells were maintained in
culture for 185 days and went through 114 population doublings
(Figure 1), at which point the experiment was terminated.
Transduction of HEL-299 cells with a retroviral vector that either
expresses the green fluorescent protein or contains a deletion in
hTERT failed to extend the life span of the HEL-299s (data not
shown). These results demonstrate that expression of hTERT
significantly extends the life span of HEL-299 cells.
HEL-TERT Cells Contain Active Telomerase
To establish that transduced hTERT resulted in telomerase
activity in HEL-TERT cells, we performed TRAP assays. In this
assay, telomerase activity is monitored by examining the laddering
or amplification of 6 base-pair 59TTAGGG39 telomeric repeats
[59]. HeLa cells, which express hTERT [60], exhibited the
characteristic 6 bp laddering, while the non-immortalized HEL-
299 failed to do so (Figure 2). Unlike the parental cell line, the
HEL-TERT cells showed a clear laddering effect, indicating that
exogenous hTERT is active and capable of extending telomeres.
As a control, we determined that our samples did not contain a
PCR inhibitor by amplifying the cellular promyelocytic leukemia
(PML) gene (data not shown). Thus, HEL-TERT cells contain
active telomerase, suggesting that the extended proliferative
capacity of this cell line can be attributed to the maintenance of
telomeres.
Prolonged Culture of HEL-TERTs does not Result in
Senescence
As fibroblasts reach senescence, they exhibit characteristic
changes in cellular morphology, such as an increase in area, due to
dysregulation of cytoskeleton elements [5,61]. Additionally,
senescent cells can be detected by their upregulation of a
lysosomal b-galactosidase [62]. When we compared low (6
population doublings) and high (20 population doublings) passage
HEL-299 cells, we noted that many of the higher passage cells
exhibited a clear enlargement of the cytoplasm, with a change
from their typical narrow, drawn-out morphology to one that was
shortened and/or broader (Figure 3A). When we compared the
HEL-TERT cells to low passage HEL-299 cells, we were able to
Figure 1. HEL-TERT cells are life-extended compared to HEL-299 cells. HEL-TERT and HEL-299 cells were plated as duplicate cultures in 60
mm dishes at 16105 and 26105 cells per plate, respectively. For each passaging, cells were counted and re-plated. Population doublings were
determined by using cell counts and days in culture.
doi:10.1371/journal.pone.0058233.g001
hTERT Does Not Affect Interferon Signaling
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e58233
detect little if any morphological changes either shortly after
transduction with hTERT or at 100 population doublings later
(Figure 3A). As part of these studies, we also examined another
HEL-TERT derivative cell line that expresses SV40 large Tag
(hereafter named HEL-TERT-T). SV40 large Tag is known to
alter the IFN-response [63]. From this experiment, HEL-TERT-T
cells appeared to have an altered cellular morphology, with the
cells decreasing in length and broadening in width. When we
examined all the cell types for senescence-associated b-galactosi-
dase activity, b-galactosidase activity was clearly detected in older
HEL-299 cells, whereas we failed to detect b-galactosidase activity
in either low passage HEL-299 or low or high passage HEL-
TERT, or high passage HEL-TERT-T cells (Figure 3B). These
results indicate that not only do HEL-TERT cells retain their
ability to proliferate but also fail to exhibit signs of senescence.
Treatment of HEL-TERT Cells with Human IFN-b Induces
Strong ISG Expression
Because the IFN response has been reported to be altered in
immortalized cells [2–4], we decided to examine the effect that
exogenous hTERT had on ISG levels. HEL-299, HEL-TERT,
and HEL-TERT-T cells were stimulated with IFN-b for 9 h and
the transcript levels of four prototypic ISGs (ISG15, IFIT1, IFIT2,
and Mx1) were monitored by qRT-PCR. Both HEL-299 and
HEL-TERT cells showed robust upregulation in the transcript
levels of all four genes after the addition of IFN-b (Figure 4). Three
of the ISGs induced to similar levels between the two cell lines
while ISG15 was induced to slightly higher levels in the HEL-
TERTs. On the other hand, the overall upregulation of these
genes upon IFN-b treatment was greatly diminished in HEL-
TERT-T cells. When we examined IFIT1 protein levels, we found
that, as expected [64], unstimulated HEL-299 and HEL-TERT
cells contained little to no detectable IFIT1; however, IFIT1 was
readily detected 9 hours after IFN-b treatment (Figure 5). Notably,
IFN-treated HEL-299 and HEL-TERT cells showed comparable
levels of IFIT1 protein. HEL-TERT-T cells, on the other hand,
showed persistent production of IFIT1 and a greatly reduced
difference between the unstimulated and IFN-treated states (as
compared to that found in the other two cell lines), in agreement
with a previous report [65]. Thus, the ectopic expression of
hTERT in HEL-299 cells via retroviral transduction does not
largely affect the ability of HEL cells to induce the expression of
these four ISGs by IFN-b nor does it lead to a dysregulation of
ISG protein production (i.e., IFIT1) as does expression of TAg.
HSV-1 and VSV Replicate to Comparable Levels, +/2 IFN-
b, in HEL-299 and HEL-TERT Cells
As another measure to assess whether the IFN response is active
and functional in HEL-TERT cells, we examined the replication
of three viruses in the presence of IFN-b. For these studies, we
chose HSV-1, which is largely resistant to type I IFNs, as well as
both an ICP0-null mutant of HSV-1 and VSV, as these latter two
viruses are sensitive to type I IFNs [66–68]. Initially, we examined
the ability of wildtype (WT) and ICP0-null HSV-1 to form plaques
on untreated and IFN-b-treated HEL-299, HEL-TERT, and
HEL-TERT-T cells. Both viruses had visually comparable plaque
sizes on both HEL-299 and HEL-TERT cell types (Figure 6), even
on higher passage HEL-TERT cells (data not shown). Plaques
appeared to be slightly smaller on HEL-TERT-T cells, which is
most likely due a decrease in the size of the cells that occurred
upon transduction of TAg (Figure 3A). When the cells were
pretreated with IFN-b, there was a large decrease in plaque size
for both WT HSV-1 and the ICP0-null mutant on HEL-299 and
HEL-TERT cells, while plaque size on the HEL-TERT-T cells
remained largely the same. The ability of WT virus to form
plaques was similar on the three cell lines in untreated cells
(Figure 7A), though the ICP0-null virus showed slight increases of
2-fold and 4.5-fold on HEL-TERT and HEL-TERT-T cells,
respectively. Upon the addition of IFN-b, the plaquing efficiencies
of the WT and ICP0-null viruses were decreased ,10 fold and
,50-100-fold, respectively, on both HEL-299 and HEL-TERT
cells (Figure 7C). In contrast to the introduction of hTERT into
HEL-299 cells, expression of large TAg greatly diminished the
ability of IFN-b to restrict the plaquing of either WT or the ICP0-
null virus (3-fold for either) (Figure 7C), resulting in a nearly 80-
fold increase in the plating efficiency of the ICP0-null virus on
IFN-treated HEL-TERT-T cells as compared to IFN-treated
HEL-299 cells (Figure 7B). To further examine the effect of
hTERT on HSV-1 replication, we also performed viral yield
assays in the three cell types. (Figure 7D). WT HSV-1 replicated to
comparable levels in all three cell lines, with IFN-pretreatment
producing a slight reduction in yields from both HEL-299 and
HEL-TERT but not from HEL-TERT-T cells. Like WT HSV-1,
the ICP0-null mutant replicated nearly as well among the three
cell types in untreated cells; however, IFN-pretreatment resulted in
a 100-fold decrease of viral yields in HEL-299 and HEL-TERT
cells while producing little to no effect in HEL-TERT-T cells.
To monitor reductions in VSV production, we again performed
viral yield assays in the presence and absence of IFN-b. Just as for
HSV-1, VSV grew equally well among the three cell lines in
untreated cells. In IFN-b-treated cells, however, VSV growth in
both HEL-299 and HEL-TERT cells was reduced by .106-fold
while it was reduced by only 200-fold in pretreated HEL-TERT-T
cells (Figure 8). Thus, HEL-TERT cells are similar to HEL-299s in
their ability to support the replication of two genetically distinct
Figure 2. Telomerase activity is detectable in HEL-TERT and
HeLa cells but not HEL-299 cells. HEL-299 (3 population doublings),
HEL-TERT (3 population doublings), and HeLa cells were examined for
telomerase activity using the TRAP assay. HeLa cells were used as a
positive control for telomerase activity. The numbers at the left side of
the figure are DNA size markers (bp: base pair).
doi:10.1371/journal.pone.0058233.g002
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viruses, and they retain an IFN response that is as functional as the
parental cell line. Overall, ectopically expressed hTERT does not
appear to adversely affect viral replication or the type I IFN
response in a human lung fibroblast cell strain.
Effect of hTERT on Antiviral Cytokine Production
In addition to determining its effect on ISG upregulation and on
the efficacy of an IFN-induced antiviral state, we decided to assess
whether ectopic hTERT expression altered the ability of cells to
produce IFN and other antiviral cytokines in response to infection.
Figure 3. HEL-299, HEL-TERT, and HEL-TERT-T cell morphology and senescence. A. Transduction of HEL-299 cells with hTERT does not
alter morphology. Light microscopy of live HEL-299 cells at 3 (left panel) and 22 population doublings (left middle panel), HEL-TERT cells after 6
(middle panel) and 100 (right middle panel), and HEL-TERT-T (far right panel) after approximately 30 population doublings. B. HEL-TERT cells fail to
exhibit at least one sign of senescence. HEL-299 cells at 6 (left panel) and 33 (left middle panel), HEL-TERT cells after 42 (right middle panel), and HEL-
TERT-T cells at approximately 70 (right panel) population doublings were stained for b-galactosidase activity.
doi:10.1371/journal.pone.0058233.g003
Figure 4. HEL-TERT but not HEL-TERT-T cells show ISG induction at levels similar to HEL-299 cells after IFN stimulation. HEL-299 and
HEL-TERT cells were treated or mock treated with 1000 U/mL of human IFN-b. At 9 hours post treatment, total RNA was isolated from cells and
reversed transcribed into cDNA for qRT-PCR analysis to monitor IFIT1, IFIT2, ISG15, and Mx1 transcript levels. Data represents the means of 6 samples;
error bars represent the standard errors of the means. *p,0.05, one-way ANOVA, Bonferroni’s multiple comparison post-test, compared to HEL-299
levels.
doi:10.1371/journal.pone.0058233.g004
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We used infection by SeV, which is known to be a strong inducer
of IFNs and other antiviral cytokines in human cells [69]. For this
assay, media from uninfected and infected HEL cells are placed
onto naı̈ve Vero cells, which respond to but cannot produce IFN,
and restrictions on VSV plaquing are monitored [70,71]. Media
from mock-infected HEL cells had no effect on the ability of VSV
to plaque on Vero cells while IFN-b pretreatment, at the highest
level tested (1000 U/mL), was able to reduce the number of
plaques formed by approximately 35-fold (Table 1). When we
tested the ability of media from SeV-infected HEL cells, we found
that media from all three cell types were capable of lowering the
number of plaques that formed by 5–7 fold. These reductions were
similar to the antiviral activity of 100 U/mL of IFN-b. Although
we are unable to distinguish between IFN-b or among the IFN-a
subtypes with this assay, the protective effect produced by media
from HEL-299 and HEL-TERT cells was identical and suggests
that hTERT does not affect the activation of IFN-production in
response to viral infection.
Discussion
Due to their unperturbed DNA damage, senescence, and
antiviral pathways, primary cells are considered biologically
relevant cells when studying how these cellular processes affect
viral replication. However, their limited ability to proliferate
makes their use in examining these pathways technically
challenging. For example, the establishment of a cell line depleted
for a particular cellular protein is generally difficult to generate
because of the rapid and inevitable onset of senescence. Thus, in
studying cell-virus interactions, there is a need for life-extended
cell lines that retain many of the characteristics of a primary cell
(e.g., antiviral responses) while allowing for the analysis of specific
cellular genes or proteins (e.g., depletion, gene knockout). It is
possible to immortalize primary cells with viral and cellular
oncoproteins, but immortalization can result in alterations of
cellular processes and inhibit antiviral pathways, affecting the
replication of wild-type and mutant viruses [72–75]. Another
approach is to use the TERT gene, which has been reported to
extend the life of human fibroblasts [36], and avoids many of the
problems associated with cellular or viral oncogene immortaliza-
tion or transformation [39]. Prior to this study, the effect of
hTERT expression on the IFN response had not, to the best of our
knowledge, been examined.
The traditional approach used to immortalize primary cells has
been the introduction of cellular or viral oncogenes. The most
commonly used of these include E1A and E1B from adenovirus
[76], E6 and E7 from human papillomavirus [17], and large TAg
from SV40 [20,77]. In general, these proteins bypass senescence
by the inactivation of one or both of the tumor suppressor
proteins, p53 and pRb [78–80]. Unfortunately, in addition to
perturbing the cell cycle, many of these viral proteins also serve to
antagonize or inactivate antiviral pathways in order to promote
viral replication. E1A, E6, E7, and large TAg are capable of
disrupting the activity of, among others, cellular histone
deacetylases [81] and CBP/p300 [82–84] resulting in widespread
transcriptional and epigenetic changes [85–89]. In the case of
Figure 5. IFIT1 protein production is induced to similar levels by IFN-b in HEL-299 and HEL-TERT cells. HEL-299, HEL-TERT, and HEL-
TERT-T cells were mock treated or treated with 1000 U/mL of IFN-b and harvested 9 hours later. Cell lysates were analyzed for IFIT1 or b-actin protein
production by western blot.
doi:10.1371/journal.pone.0058233.g005
Figure 6. HSV-1 shows similar plaque size and morphology on HEL-299 and HEL-TERT cells. HEL-299, HEL-TERT, and HEL-TERT-T cells
were mock or pretreated with IFN-b for 16 h and then infected with WT HSV-1 or an ICP0-null mutant, and plaques for both viruses were visualized by
immunohistochemistry three days post-infection. Bar = 1 mm.
doi:10.1371/journal.pone.0058233.g006
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E1A, this interaction prevents the major type I IFN transcription
factor, STAT1, from binding to CBP/p300 and upregulating ISGs
[90]. Likewise, E6 is capable of preventing activation of the IFN
response by blocking the transcriptional activity of IRF3 [91]. E1B
proteins inhibit apoptosis and are capable of inactivating the
cellular DNA damage response [92–94]. Large TAg, on the other
hand, has recently been reported to activate STAT1 and induce
ISGs upregulation in the absence of IFN-exposure [65]. In
agreement with this, we saw persistent production of IFIT1
protein in TAg-transduced cells. However, the expression of large
TAg, independent of SV40 infection, has also been shown to
decrease the phosphorylation of the cellular translation factor
eIF2a by an IFN effector, double-stranded RNA protein kinase
(PKR) [95]. This decrease in phosphorylation increases the
translation capability of viral mRNAs. Similarly, our results show
that while large TAg may lead to high levels of ISG protein
production, it functionally inactivates the IFN response. Further-
more, immortalization by mechanisms not involving viral onco-
genes may inactivate antiviral pathways, as observed with the loss
of induction of ISGs in immortalized cells derived from Li-
Fraumeni patients [1].
Our approach in this study was to extend the life of human
fibroblasts with hTERT. Cells transformed with hTERT arrest in
response to serum starvation, maintain anchorage dependence,
double at a rate similar to untransformed cells, and do not exhibit
genomic instability [39]. While it has been reported that
expression of hTERT can alter the expression of a limited
number of genes, none of these have an apparent role in antiviral
pathways [96]. We found that hTERT expression does not
interfere with the upregulation of four representative ISGs (ISG15,
IFIT1, IFIT2, and Mx1), does not lead to aberrant ISG protein
production, nor does its expression affect the replication of two
genetically distinct viruses, HSV-1 and VSV. This is in agreement
with previous work demonstrating that exogenous expression of
hTERT in fibroblasts does not affect the replication of human
cytomegalovirus [97,98] nor does it affect the upregulation of the
IFN-induced senescence mediator, IFI16, upon IFN-stimulation
[99]. Furthermore, unlike SV40 large TAg, exogenous hTERT
Figure 7. Replication of HSV-1 is diminished by IFN-b in HEL-299 and HEL-TERT but not HEL-TERT-T cells. A and B. HEL-299, HEL-TERT,
and HEL-TERT-T cells were mock (A) or pre-treated with IFN-b (1000 U/mL) (B) and were infected 16 h post treatment with 10-fold serially diluted
stocks of WT HSV-1 or an ICP0-null mutant. Plaques were visualized by immunohistochemistry 3 days post-infection. An average of three experiments
is shown. Data is presented as the ratio of plaques formed on the indicated cell line to that on HEL-299 cells. C. Data generated for A and B, but
presented as a ratio of the number of plaques formed on mock-treated cells compared to that on IFN-treated cells. D. HEL-299, HEL-TERT, and HEL-
TERT-T cells were mock or pre-treated with IFN-b (1000 U/mL) and were infected (16 h post treatment) with either WT HSV-1 or the ICP0-null mutant
at an MOI of 5 PFU/cell. Samples were harvested 24 h post-infection. Viral titers were determined by plaque assays. An average of three experiments
is shown. In all cases, error bars represent the standard errors of the means.
doi:10.1371/journal.pone.0058233.g007
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did not impair the ability of IFN to restrict the replication of VSV
or an ICP0-null mutant of HSV-1, both viruses being quite
sensitive to the effects of IFN-b, nor did it hinder the ability of
HEL cells to produce antiviral cytokines in response to viral
infection. While we did observe slight differences in the levels of
induction for the four ISGs between HEL-299 and HEL-TERT
cells, these differences failed to translate into an appreciable effect
on the ability of IFN-b to suppress replication of VSV or the ICP0-
null HSV-1 mutant. hTERT overexpression has been reported to
enhance the formation of apoptotic markers during HSV-1
infection in HeLa cells, which express the human papillomavirus
E6 and E7 oncoproteins, and sensitizes them to apoptosis [100].
Our results, however, suggest that exogenous expression of hTERT
in a primary cell strain has little impact on viral replication.
In conclusion, HEL-TERTs are permissive for HSV-1 and
VSV growth, have a robust antiviral response, and a significantly
enhanced lifespan. They recapitulate the phenotype of an HSV-1
ICP0-mutant, which is known to be complemented by the loss of
proteins involved in the DNA damage response [101], antiviral
pathways [102], or overexpression of certain cyclins [103],
suggesting that these pathways are unperturbed. Because the
phenotypes of certain HSV-1 mutants are only apparent in
primary cells, we believe the HEL-TERT cell line to be an ideal
choice due to their longevity and robust antiviral response.
Additionally, they will allow for the establishment of derivative cell
lines that are depleted or overexpress targets of interest, facilitating
a better understanding of cellular pathways (including the IFN
response) and the viruses that alter these pathways.
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